Grant Zeng, CFA
Research analyst, CFA, biotech, small-cap

Neogenomics: A Low Risk, High Return Stock To Own

Since I initiated coverage of Neogenomics (NASDAQ:NEO) in mid-October, 2011, share price of the company almost tripled as of this writing. Here comes the logical question: what's next for Neogenomics?

We are still optimistic about the prospect of Neogenomics, and think there are still a plenty of room for price appreciation in the next 12 months.

Our call is based on the company's strong financials, business development and management credibility.

(click to enlarge)(click to enlarge)(click to enlarge)

Second Quarter Revenue In Line With Our Expectation

On July 31, Neogenomics reported financial results for the second quarter ending June 30, 2013.

Revenue for the second quarter was $15.6 million, unchanged from second quarter 2012 revenue. 2Q13 revenue

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details